Compare PSIX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | STTK |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.1M | 792.9M |
| IPO Year | 2011 | 2020 |
| Metric | PSIX | STTK |
|---|---|---|
| Price | $36.28 | $7.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $99.95 | $10.00 |
| AVG Volume (30 Days) | 471.6K | ★ 863.2K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | 53.02 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $416,616,000.00 | $1,000,000.00 |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $16.20 | N/A |
| P/E Ratio | $35.97 | ★ N/A |
| Revenue Growth | ★ 22.73 | N/A |
| 52 Week Low | $25.28 | $0.98 |
| 52 Week High | $119.16 | $8.33 |
| Indicator | PSIX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 50.52 |
| Support Level | $36.18 | $6.75 |
| Resistance Level | $43.89 | $7.75 |
| Average True Range (ATR) | 1.88 | 0.39 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 26.09 | 37.70 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States, and also has its presence in North America (outside of United States), Pacific Rim, Europe and Others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.